During the corresponding time, Endo International Plc saw a revenue deteriorated by -10.45 % year on year, sequentially revenue grew by 10.2 %. While revenue at the Endo International Plc's corporate clients
Endo International Plc's Comment on Sales, Marketing and Customers
The company operates through four reportable business segments: Branded Pharmaceuticals, Sterile Injectables, Generic Pharmaceuticals, and International Pharmaceuticals. Its branded products, primarily marketed through the Branded Pharmaceuticals and Sterile Injectables segments, address scientific, regulatory, legal, and technical complexities and are sold under trademarked brand names. In the U.S. market, the company obtains FDA approvals via New Drug Applications (NDAs) or Biologics License Applications (BLAs). Generic products, mainly distributed through the Sterile Injectables and Generic Pharmaceuticals segments, focus on high-barrier-to-entry products, particularly complex sterile injectables such as ready-to-use products, as well as first-to-file or first-to-market opportunities that present formulation, manufacturing, legal, or regulatory challenges. First-to-file products involve Abbreviated New Drug Applications (ANDAs) with patent challenges filed first with the FDA, potentially granting 180 days of generic marketing exclusivity. First-to-market products are the first marketed generic equivalents for reasons other than statutory exclusivity, including formulation or manufacturing difficulty.
Endo International Plc’s Comment on Sales, Marketing and Customers
The company operates through four reportable business segments: Branded Pharmaceuticals, Sterile Injectables, Generic Pharmaceuticals, and International Pharmaceuticals. Its branded products, primarily marketed through the Branded Pharmaceuticals and Sterile Injectables segments, address scientific, regulatory, legal, and technical complexities and are sold under trademarked brand names. In the U.S. market, the company obtains FDA approvals via New Drug Applications (NDAs) or Biologics License Applications (BLAs). Generic products, mainly distributed through the Sterile Injectables and Generic Pharmaceuticals segments, focus on high-barrier-to-entry products, particularly complex sterile injectables such as ready-to-use products, as well as first-to-file or first-to-market opportunities that present formulation, manufacturing, legal, or regulatory challenges. First-to-file products involve Abbreviated New Drug Applications (ANDAs) with patent challenges filed first with the FDA, potentially granting 180 days of generic marketing exclusivity. First-to-market products are the first marketed generic equivalents for reasons other than statutory exclusivity, including formulation or manufacturing difficulty.
Sources:
Endo International Plc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Endo International Plc’s corporate clients.
For your research, we’ve provided 9 tables on Endo International Plc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
